Related Experiment Video

Updated: Aug 8, 2026

Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

Pre-clinical development of farnesyltransferase inhibitors

R B Lobell1, N E Kohl

  • 1Department of Cancer Research, Merck Research Laboratories, West Point, USA.

Cancer Metastasis Reviews
|October 14, 1998
PubMed

Insights

Farnesyl-protein transferase inhibitors (FTIs) show promise in cancer therapy by targeting the Ras oncogene. While effective against tumors with limited toxicity, their complex mechanism of action requires further investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The Ras oncogene is prevalent in human cancers, particularly pancreatic and colon cancers.
  • C-terminal lipid modification of Ras, catalyzed by farnesyl-protein transferase (FPTase), is crucial for Ras protein function.
  • Farnesyl-protein transferase inhibitors (FTIs) were developed as a targeted cancer therapy against the Ras oncogene.

Purpose of the Study:

  • To investigate the therapeutic potential of FPTase inhibitors (FTIs) in cancer treatment.
  • To explore the mechanism of action of FTIs beyond their initial conceptualization as Ras-specific agents.

Main Methods:

  • Review of existing research on Ras oncogene, FPTase, and FTIs.
  • Analysis of preclinical data from cell culture and animal tumor models.

Main Results:

  • FTIs demonstrate potent antiproliferative activity against cancer cells.
  • FTIs exhibit minimal toxicity in normal tissues.
  • The mechanism of action of FTIs is more complex than initially assumed.

Conclusions:

  • FTIs represent a promising therapeutic strategy for cancers driven by the Ras oncogene.
  • Further research is needed to fully elucidate the multifaceted mechanism of FTIs.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...